Moleculin to Participate in the Virtual Investor Lunch Break Series
Moleculin Biotech (Nasdaq: MBRX) announced its participation in the Virtual Investor Lunch Break: The Moleculin Opportunity event scheduled for June 12, 2024, at 12:00 PM ET. Walter Klemp, Chairman and CEO, will provide a corporate overview and business outlook. The event includes a live Q&A session where attendees can submit questions. A live webcast will be available on Moleculin's website, with a replay accessible for 90 days.
- Participation in the Virtual Investor Lunch Break event increases Moleculin's visibility among investors.
- Live Q&A session allows for direct engagement with stakeholders, potentially boosting investor confidence.
- Webcast replay availability for 90 days increases the accessibility of the information presented.
- No new clinical data or financial performance metrics are provided in the announcement.
- The event relies heavily on the CEO's presentation skills, which could affect investor perception.
- Potential for new information may not significantly impact the stock price.
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Klemp will answer as many questions as possible in the time allowed.
A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data related to its active clinical trials are subject to change.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-series-302163997.html
SOURCE Moleculin Biotech, Inc.
FAQ
When is Moleculin Biotech participating in the Virtual Investor Lunch Break event?
What will Walter Klemp discuss during the Moleculin Opportunity event?
How can I watch the Moleculin Opportunity event live?
Will there be a replay available for the Moleculin Opportunity event?
What is the stock symbol for Moleculin Biotech?
